
Insulet (PODD) Stock Forecast & Price Target
Insulet (PODD) Analyst Ratings
Bulls say
Insulet is facing some supply chain and manufacturing dependencies that could impact distribution and sales, but the recent launch of its Omnipod 5 automated insulin delivery system shows potential for future growth. Despite recent concerns about lower utilization and retention trends in the US Type 2 population, strong international momentum and profitability, coupled with the company's efforts to improve commercial execution, warrant a neutral rating. There are some risks to achieving the company's price target, such as competition, technology risk, and geopolitical risk, but overall, Insulet's unique product and potential for international growth provide a positive outlook.
Bears say
Insulet is facing several significant challenges that could negatively impact their financial performance and stock value. These challenges include increased competition from new entrants in the tubeless insulin pump market, potential loss of market share in the T2D population due to lower utilization and retention trends, and potential cybersecurity threats for their devices. These challenges, coupled with uncertainty surrounding management's credibility, may lead to lower revenue growth and profitability for the company in the coming years.
This aggregate rating is based on analysts' research of Insulet and is not a guaranteed prediction by Public.com or investment advice.
Insulet (PODD) Analyst Forecast & Price Prediction
Start investing in Insulet (PODD)
Order type
Buy in
Order amount
Est. shares
0 shares